Exosomes in India: Exsure Leading Exosome Drug Delivery & Cancer Therapeutics
Exosomes—natural nanoscale extracellular vesicles (~30–150 nm)—are rapidly emerging as high-impact biological delivery vehicles in drug delivery, diagnostics, and regenerative medicine. They offer innate stability, biocompatibility, and precise uptake by target cells, making them compelling alternatives to synthetic nanocarriers.
India’s scientific ecosystem is participating in this global shift, and at the forefront is Exsure, whose research and platforms are advancing exosome-based therapeutics toward clinical relevance.
Exsure’s Contributions: Pushing the Frontier of Exosome Drug Delivery
1. ExoDS — Targeted Delivery to Cancer Cells & Cancer Stem Cells
In a peer-reviewed study published in Frontiers in Bioengineering and Biotechnology, the Exsure research team developed ExoDS, an exosome-based drug delivery platform designed to encapsulate chemotherapy drugs and enhance precision targeting to cancer cells and cancer stem cells.
Key findings from the ExoDS study:
- ExoDS was produced by isolating exosomes from mature dendritic cells and loading them with doxorubicin, a widely used chemotherapeutic.
- These exosomes showed preferential uptake by breast cancer cells and cancer stem cells while sparing healthy cells, including peripheral blood mononuclear cells (PBMCs).
- ExoDS effectively targeted circulating tumor cells (CTCs) isolated from patient blood samples, highlighting potential translational relevance.
- The study demonstrated that ExoDS matched the in vivo efficacy of free doxorubicin but with enhanced target specificity and reduced off-target effects.
This publication emphasizes Exsure’s platform innovation—not just conceptual research—but functional therapeutic engineering applicable to hard-to-treat cancers.
Why Exsure Matters for Exosome Innovation in India
While India’s academic labs are actively publishing on exosome biology, Exsure bridges the gap between discovery and delivery by focusing on translatable therapeutic platforms. The company’s peer-reviewed work is among the first in India to demonstrate an engineered exosome system with potential clinical relevance.
Key capabilities developed at Exsure include:
- Scalable exosome isolation and drug loading protocols
- Targeted delivery systems for oncological applications
- Integration of bioengineering and immunological insights to enhance specificity
- Rigorous preclinical validation demonstrating selective targeting and therapeutic efficacy
By contributing both novel engineered platforms and thought leadership through publications, Exsure positions itself as a pivotal actor in India’s emergence into global exosome therapeutics.
Scientific References
- Paul S, Bhagat S, Dash L, Mohapatra HD, Jena S, Verma SK, Dutta A (2024). ExoDS: a versatile exosome-based drug delivery platform to target cancer cells and cancer stem cells. Front. Bioeng. Biotechnol. 12:1362681. https://doi.org/10.3389/fbioe.2024.1362681
- Dutta A & Paul S (2022). Advancement in exosome-based cancer therapeutics: A new era in cancer treatment. Front. Nanotechnol. 4:939197. https://doi.org/10.3389/fnano.2022.939197
- Abels ER & Breakefield XO (2016). Introduction to extracellular vesicles: Biogenesis, RNA cargo selection, content, release, and uptake. Cell. Mol. Neurobiol. 36.
